Profile
McKesson Robbinsville NJ US
McKesson Corporation, doing business as McKesson Drug Company, is a licensed wholesale distributor of drugs, cosmetics, and medical devices based at 1 John Henry Dr, Robbinsville, NJ 08691. The company is authorized by the Connecticut Department of Consumer Protection (DCP) under credential code CSW.0003214, with a license type designated as “Wholesaler of Drugs, Cosmetics & Medical Devices.” Issued on February 11, 2014, the license became effective July 1, 2021, and remains active through June 30, 2022.
As a key player in the healthcare supply chain, McKesson provides essential pharmaceutical and medical products to healthcare providers, pharmacies, and other authorized entities. The company’s operations are headquartered at its registered office in Robbinsville, NJ, reflecting its commitment to serving the region while adhering to state and federal regulatory standards. Its active license underscores compliance with rigorous industry requirements, ensuring the safe and legal distribution of critical healthcare products.
Location Reviews
McKesson, a healthcare services provider based in Robbinsville, NJ, is described on its website as a diversified leader offering drug distribution, medical supplies, and pharmacy management tools to healthcare organizations. Reviews of the company are mixed, with some positive feedback highlighting efficient services, competitive pricing, and user-friendly technology for medical supply procurement. However, the majority of customer experiences are negative, with recurring complaints about poor customer service, slow shipping, and unresponsive support. Specific issues include delays in receiving critical medical equipment (e.g., breast pumps for newborns), lack of empathy from customer service representatives, and difficulties in resolving medication shortages or supply chain problems.
Negative reviews frequently criticize McKesson’s management practices, citing high employee turnover, excessive overtime, and inadequate leadership. Some customers also express frustration with the company’s perceived lack of prioritization for individual patients, contrasting its stated mission of improving care with experiences of being treated as a secondary concern. While the company emphasizes its role in healthcare supply chain resilience and value-based care programs, these claims are not consistently reflected in customer interactions, which often highlight impersonal service and a focus on organizational efficiency over patient needs. Overall, sentiment appears split between operational strengths and significant gaps in customer support and responsiveness.